BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008;65:1031-1038. [PMID: 18695053 DOI: 10.1001/archneur.65.8.1031] [Cited by in Crossref: 208] [Cited by in F6Publishing: 212] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, Brinkmalm G, Lundkvist J, Jacobson LH, Perrot L, Neumann U, Borghys H, Mercken M, Dhuyvetter D, Jeppsson F, Blennow K, Portelius E. BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system. PLoS One 2012;7:e31084. [PMID: 22328928 DOI: 10.1371/journal.pone.0031084] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
2 Berkness T, Carrillo MC, Sperling R, Petersen R, Aisen P, Flournoy C, Snyder H, Raman R, Grill JD. The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program. J Prev Alzheimers Dis 2021;8:286-91. [PMID: 34101785 DOI: 10.14283/jpad.2021.12] [Reference Citation Analysis]
3 Li J, Llano DA, Ellis T, LeBlond D, Bhathena A, Jhee SS, Ereshefsky L, Lenz R, Waring JF. Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels. Alzheimers Dement 2012;8:295-303. [PMID: 22047633 DOI: 10.1016/j.jalz.2011.05.900] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
4 Checler F, Afram E, Pardossi-Piquard R, Lauritzen I. Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99? J Biol Chem 2021;296:100489. [PMID: 33662398 DOI: 10.1016/j.jbc.2021.100489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Xia W. Brain amyloid β protein and memory disruption in Alzheimer's disease. Neuropsychiatr Dis Treat 2010;6:605-11. [PMID: 20856923 DOI: 10.2147/NDT.S7460] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
6 Crump CJ, Johnson DS, Li YM. Development and mechanism of γ-secretase modulators for Alzheimer's disease. Biochemistry 2013;52:3197-216. [PMID: 23614767 DOI: 10.1021/bi400377p] [Cited by in Crossref: 125] [Cited by in F6Publishing: 105] [Article Influence: 15.6] [Reference Citation Analysis]
7 Xia W. γ-Secretase and its modulators: Twenty years and beyond. Neurosci Lett 2019;701:162-9. [PMID: 30763650 DOI: 10.1016/j.neulet.2019.02.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
8 Niva C, Parkinson J, Olsson F, van Schaick E, Lundkvist J, Visser SAG. Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data. Eur J Clin Pharmacol 2013;69:1247-60. [DOI: 10.1007/s00228-012-1459-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
9 Adeniji A, Adams P, Mody V. Amyloid β Hypothesis in the Development of Therapeutic Agents for Alzheimer’s Disease. Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders. Elsevier; 2017. pp. 109-43. [DOI: 10.1016/b978-0-12-802810-0.00007-6] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 Giacomini A, Stagni F, Trazzi S, Guidi S, Emili M, Brigham E, Ciani E, Bartesaghi R. Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 2015;82:385-96. [PMID: 26254735 DOI: 10.1016/j.nbd.2015.08.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
11 Schnell PM, Ball G. A Bayesian Exposure-Time Method for Clinical Trial Safety Monitoring With Blinded Data. Ther Innov Regul Sci 2016;50:833-8. [PMID: 30231731 DOI: 10.1177/2168479016656702] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
12 Mancuso C, Siciliano R, Barone E, Butterfield DA, Preziosi P. Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. Expert Opinion on Investigational Drugs 2011;20:1243-61. [DOI: 10.1517/13543784.2011.601740] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
13 Parsons CG, Rammes G. Preclinical to phase II amyloid beta (A β ) peptide modulators under investigation for Alzheimer’s disease. Expert Opinion on Investigational Drugs 2017;26:579-92. [DOI: 10.1080/13543784.2017.1313832] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
14 Mysliwiec P, Boucher MJ. Targeting Notch signaling in pancreatic cancer patients--rationale for new therapy. Adv Med Sci 2009;54:136-42. [PMID: 19758972 DOI: 10.2478/v10039-009-0026-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
15 Rogers K, Felsenstein KM, Hrdlicka L, Tu Z, Albayya F, Lee W, Hopp S, Miller MJ, Spaulding D, Yang Z, Hodgdon H, Nolan S, Wen M, Costa D, Blain JF, Freeman E, De Strooper B, Vulsteke V, Scrocchi L, Zetterberg H, Portelius E, Hutter-Paier B, Havas D, Ahlijanian M, Flood D, Leventhal L, Shapiro G, Patzke H, Chesworth R, Koenig G. Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Mol Neurodegener 2012;7:61. [PMID: 23249765 DOI: 10.1186/1750-1326-7-61] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 5.7] [Reference Citation Analysis]
16 Portelius E, Gustavsson MK, Zetterberg H, Andreasson U, Blennow K. Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient. Neurodegener Dis 2012;10:138-40. [PMID: 22302034 DOI: 10.1159/000334537] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
17 Cummings J. The Role of Biomarkers in Alzheimer's Disease Drug Development. Adv Exp Med Biol 2019;1118:29-61. [PMID: 30747416 DOI: 10.1007/978-3-030-05542-4_2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 13.5] [Reference Citation Analysis]
18 Zetterberg H, Mattsson N, Shaw LM, Blennow K. Biochemical markers in Alzheimer's disease clinical trials. Biomark Med 2010;4:91-8. [PMID: 20387305 DOI: 10.2217/bmm.09.80] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
19 Mitani Y, Akashiba H, Saita K, Yarimizu J, Uchino H, Okabe M, Asai M, Yamasaki S, Nozawa T, Ishikawa N, Shitaka Y, Ni K, Matsuoka N. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates. Neuropharmacology 2014;79:412-9. [PMID: 24373902 DOI: 10.1016/j.neuropharm.2013.12.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
20 Hsu YC, Chang PJ, Tung CW, Shih YH, Ni WC, Li YC, Uto T, Shoyama Y, Ho C, Lin CL. De-Glycyrrhizinated Licorice Extract Attenuates High Glucose-Stimulated Renal Tubular Epithelial-Mesenchymal Transition via Suppressing the Notch2 Signaling Pathway. Cells 2020;9:E125. [PMID: 31948095 DOI: 10.3390/cells9010125] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Castellani RJ, Plascencia-Villa G, Perry G. The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. Lab Invest 2019;99:958-70. [PMID: 30760863 DOI: 10.1038/s41374-019-0231-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 18.0] [Reference Citation Analysis]
22 Li T, Huang Y, Jin S, Ye L, Rong N, Yang X, Ding Y, Cheng Z, Zhang J, Wan Z, Harrison DC, Hussain I, Hall A, Lee DH, Lau LF, Matsuoka Y. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment. J Neurochem 2012;121:277-86. [PMID: 22035227 DOI: 10.1111/j.1471-4159.2011.07560.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
23 Sogorb-Esteve A, García-Ayllón MS, Llansola M, Felipo V, Blennow K, Sáez-Valero J. Inhibition of γ-Secretase Leads to an Increase in Presenilin-1. Mol Neurobiol 2018;55:5047-58. [PMID: 28815510 DOI: 10.1007/s12035-017-0705-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
24 Bergmans BA, De Strooper B. gamma-secretases: from cell biology to therapeutic strategies. Lancet Neurol. 2010;9:215-226. [PMID: 20129170 DOI: 10.1016/s1474-4422(09)70332-1] [Cited by in Crossref: 106] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
25 Panza F, Frisardi V, Imbimbo BP, Capurso C, Logroscino G, Sancarlo D, Seripa D, Vendemiale G, Pilotto A, Solfrizzi V. REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer’s disease: The current state. CNS Neurosci Ther. 2010;16:272-284. [PMID: 20560993 DOI: 10.1111/j.1755-5949.2010.00164.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
26 Hsu CH, Jiang YJ. Does Nicastrin Inadequacy Cause Melanocytotoxicity in Human Skin as in the Fish Counterpart? J Invest Dermatol 2021;141:1334-8. [PMID: 33058861 DOI: 10.1016/j.jid.2020.09.016] [Reference Citation Analysis]
27 Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, Liu-Seifert H, Hake AM, Miller DS, Doody RS, Henley DB, Cummings JL. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimers Res Ther 2015;7:39. [PMID: 26120368 DOI: 10.1186/s13195-015-0122-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
28 Hsu CH, Liou GG, Jiang YJ. Nicastrin Deficiency Induces Tyrosinase-Dependent Depigmentation and Skin Inflammation. J Invest Dermatol 2020;140:404-414.e13. [PMID: 31437444 DOI: 10.1016/j.jid.2019.07.702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9:560-574. [PMID: 20592748 DOI: 10.1038/nrd3115] [Cited by in Crossref: 404] [Cited by in F6Publishing: 421] [Article Influence: 36.7] [Reference Citation Analysis]
30 Yang T, Arslanova D, Gu Y, Augelli-Szafran C, Xia W. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein. Mol Brain 2008;1:15. [PMID: 18983676 DOI: 10.1186/1756-6606-1-15] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
31 Torrice A, Cardinale V, Gatto M, Semeraro R, Napoli C, Onori P, Alpini G, Gaudio E, Alvaro D. Polycystins play a key role in the modulation of cholangiocyte proliferation. Dig Liver Dis. 2010;42:377-385. [PMID: 19897428 DOI: 10.1016/j.dld.2009.09.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
32 Wells EM, Nageswara Rao AA, Scafidi J, Packer RJ. Neurotoxicity of biologically targeted agents in pediatric cancer trials. Pediatr Neurol 2012;46:212-21. [PMID: 22490765 DOI: 10.1016/j.pediatrneurol.2012.02.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Yi P, Hadden C, Kulanthaivel P, Calvert N, Annes W, Brown T, Barbuch RJ, Chaudhary A, Ayan-oshodi MA, Ring BJ. Disposition and Metabolism of Semagacestat, a γ-Secretase Inhibitor, in Humans. Drug Metab Dispos 2010;38:554-65. [DOI: 10.1124/dmd.109.030841] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
34 Quinn JF. Biomarkers for Alzheimer's disease: showing the way or leading us astray? J Alzheimers Dis 2013;33 Suppl 1:S371-6. [PMID: 22766735 DOI: 10.3233/JAD-2012-129022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
35 Wendler A, Wehling M. Translatability scoring in drug development: eight case studies. J Transl Med 2012;10:39. [PMID: 22397594 DOI: 10.1186/1479-5876-10-39] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
36 Biran Y, Masters CL, Barnham KJ, Bush AI, Adlard PA. Pharmacotherapeutic targets in Alzheimer's disease. J Cell Mol Med 2009;13:61-86. [PMID: 19040415 DOI: 10.1111/j.1582-4934.2008.00595.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
37 Kumar D, Ganeshpurkar A, Kumar D, Modi G, Gupta SK, Singh SK. Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead. European Journal of Medicinal Chemistry 2018;148:436-52. [DOI: 10.1016/j.ejmech.2018.02.035] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 25.0] [Reference Citation Analysis]
38 Doens D, Valdés-Tresanco ME, Vasquez V, Carreira MB, De La Guardia Y, Stephens DE, Nguyen VD, Nguyen VT, Gu J, Hegde ML, Larionov OV, Valiente PA, Lleonart R, Fernández PL. Hexahydropyrrolo[2,3-b]indole Compounds as Potential Therapeutics for Alzheimer's Disease. ACS Chem Neurosci 2019;10:4250-63. [PMID: 31545596 DOI: 10.1021/acschemneuro.9b00297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
39 Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y, Ni K, Matsuoka N. Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci 2012;32:2037-50. [PMID: 22323718 DOI: 10.1523/JNEUROSCI.4264-11.2012] [Cited by in Crossref: 136] [Cited by in F6Publishing: 77] [Article Influence: 15.1] [Reference Citation Analysis]
40 Canter RG, Penney J, Tsai LH. The road to restoring neural circuits for the treatment of Alzheimer's disease. Nature. 2016;539:187-196. [PMID: 27830780 DOI: 10.1038/nature20412] [Cited by in Crossref: 243] [Cited by in F6Publishing: 218] [Article Influence: 48.6] [Reference Citation Analysis]
41 Grill JD, Karlawish J. Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res Ther 2010;2:34. [PMID: 21172069 DOI: 10.1186/alzrt58] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 7.1] [Reference Citation Analysis]
42 Gabrielsson J, Peletier LA. Mixture dynamics: Dual action of inhibition and stimulation. European Journal of Pharmaceutical Sciences 2013;50:215-26. [DOI: 10.1016/j.ejps.2013.06.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
43 Rosenmann H. CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease. J Mol Neurosci 2012;47:1-14. [DOI: 10.1007/s12031-011-9665-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
44 Lanctôt KL, Rajaram RD, Herrmann N. Therapy for Alzheimer's Disease: How Effective are Current Treatments? Ther Adv Neurol Disord 2009;2:163-80. [PMID: 21179526 DOI: 10.1177/1756285609102724] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
45 Evin G. Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors. BioDrugs 2016;30:173-94. [PMID: 27023706 DOI: 10.1007/s40259-016-0168-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
46 Kanwar JR, Sriramoju B, Kanwar RK. Neurological disorders and therapeutics targeted to surmount the blood-brain barrier. Int J Nanomedicine 2012;7:3259-78. [PMID: 22848160 DOI: 10.2147/IJN.S30919] [Cited by in Crossref: 55] [Cited by in F6Publishing: 17] [Article Influence: 6.1] [Reference Citation Analysis]
47 Sawa M, Overk C, Becker A, Derse D, Albay R, Weldy K, Salehi A, Beach TG, Doran E, Head E, Yu YE, Mobley WC. Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model. Alzheimers Dement 2021. [PMID: 34757693 DOI: 10.1002/alz.12463] [Reference Citation Analysis]
48 Murakami K, Watanabe T, Koike T, Kamata M, Igari T, Kondo S. Pharmacological properties of a novel and potent γ-secretase modulator as a therapeutic option for the treatment of Alzheimer's disease. Brain Res 2016;1633:73-86. [PMID: 26707977 DOI: 10.1016/j.brainres.2015.12.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
49 Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother 2009;10:1657-64. [PMID: 19527190 DOI: 10.1517/14656560903044982] [Cited by in Crossref: 109] [Cited by in F6Publishing: 100] [Article Influence: 9.1] [Reference Citation Analysis]
50 Golde TE, Petrucelli L, Lewis J. Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol 2010;223:252-66. [PMID: 19716367 DOI: 10.1016/j.expneurol.2009.07.035] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 5.0] [Reference Citation Analysis]
51 Anthony DP, Hegde M, Shetty SS, Rafic T, Mutalik S, Rao BSS. Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases. Life Sci 2021;274:119326. [PMID: 33711385 DOI: 10.1016/j.lfs.2021.119326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Grill JD, Cummings JL. Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev Neurother 2010;10:711-28. [PMID: 20420492 DOI: 10.1586/ern.10.29] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 6.5] [Reference Citation Analysis]
53 Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, Roberts C, McCleery J, Pickett J, Bunn F, Challis D, Charlesworth G, Featherstone K, Fox C, Goodman C, Jones R, Lamb S, Moniz-Cook E, Schneider J, Shepperd S, Surr C, Thompson-Coon J, Ballard C, Brayne C, Burke O, Burns A, Clare L, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Murtagh F, Robinson L, Livingston G. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technol Assess 2017;21:1-192. [PMID: 28625273 DOI: 10.3310/hta21260] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
54 Goda R, Kobayashi N. Evaluation of peptide adsorption-controlled liquid chromatography–tandem mass spectrometric (PAC-LC–MS/MS) method for simple and simultaneous quantitation of amyloid β 1–38, 1–40, 1–42 and 1–43 peptides in dog cerebrospinal fluid. Journal of Chromatography B 2012;895-896:137-45. [DOI: 10.1016/j.jchromb.2012.03.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
55 Albright CF, Dockens RC, Meredith JE Jr, Olson RE, Slemmon R, Lentz KA, Wang JS, Denton RR, Pilcher G, Rhyne PW, Raybon JJ, Barten DM, Burton C, Toyn JH, Sankaranarayanan S, Polson C, Guss V, White R, Simutis F, Sanderson T, Gillman KW, Starrett JE Jr, Bronson J, Sverdlov O, Huang SP, Castaneda L, Feldman H, Coric V, Zaczek R, Macor JE, Houston J, Berman RM, Tong G. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat. J Pharmacol Exp Ther 2013;344:686-95. [PMID: 23275065 DOI: 10.1124/jpet.112.199356] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
56 Vorobyeva AG, Lee R, Miller S, Longen C, Sharoni M, Kandelwal PJ, Kim FJ, Marenda DR, Saunders AJ. Cyclopamine modulates γ-secretase-mediated cleavage of amyloid precursor protein by altering its subcellular trafficking and lysosomal degradation. J Biol Chem 2014;289:33258-74. [PMID: 25281744 DOI: 10.1074/jbc.M114.591792] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
57 Zhao J, Liu X, Xia W, Zhang Y, Wang C. Targeting Amyloidogenic Processing of APP in Alzheimer's Disease. Front Mol Neurosci 2020;13:137. [PMID: 32848600 DOI: 10.3389/fnmol.2020.00137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
58 Ayalon L. Willingness to Participate in Alzheimer Disease Research and Attitudes Towards Proxy-Informed Consent: Results From the Health and Retirement Study. The American Journal of Geriatric Psychiatry 2009;17:65-74. [DOI: 10.1097/jgp.0b013e31818cd3d3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
59 Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'onofrio G, Logroscino G, Seripa D, Pilotto A. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? Expert Opinion on Investigational Drugs 2011;20:325-41. [DOI: 10.1517/13543784.2011.550572] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
60 Cole DC, Bursavich MG. Nonpeptide BACE1 Inhibitors: Design and Synthesis. In: Ghosh AK, editor. Aspartic Acid Proteases as Therapeutic Targets. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2010. pp. 481-509. [DOI: 10.1002/9783527630943.ch17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Blennow K. Biomarkers in Alzheimer's disease drug development. Nat Med. 2010;16:1218-1222. [PMID: 21052077 DOI: 10.1038/nm.2221] [Cited by in Crossref: 86] [Cited by in F6Publishing: 87] [Article Influence: 7.8] [Reference Citation Analysis]
62 Rynearson KD, Ponnusamy M, Prikhodko O, Xie Y, Zhang C, Nguyen P, Hug B, Sawa M, Becker A, Spencer B, Florio J, Mante M, Salehi B, Arias C, Galasko D, Head BP, Johnson G, Lin JH, Duddy SK, Rissman RA, Mobley WC, Thinakaran G, Tanzi RE, Wagner SL. Preclinical validation of a potent γ-secretase modulator for Alzheimer's disease prevention. J Exp Med 2021;218:e20202560. [PMID: 33651103 DOI: 10.1084/jem.20202560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
63 Kreft AF, Martone R, Porte A. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J Med Chem 2009;52:6169-88. [PMID: 19694467 DOI: 10.1021/jm900188z] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 6.5] [Reference Citation Analysis]
64 Huang Y, Li T, Eatherton A, Mitchell WL, Rong N, Ye L, Yang X, Jin S, Ding Y, Zhang J, Li Y, Wu Y, Jin Y, Sang Y, Cheng Z, Browne ER, Harrison DC, Hussain I, Wan Z, Hall A, Lau L, Matsuoka Y. Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ-secretase modulators reduced amyloidogenic Aβ peptides in vivo. Neuropharmacology 2013;70:278-86. [DOI: 10.1016/j.neuropharm.2013.02.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
65 Lucey BP, Gonzales C, Das U, Li J, Siemers ER, Slemmon JR, Bateman RJ, Huang Y, Fox GB, Claassen JA, Slats D, Verbeek MM, Tong G, Soares H, Savage MJ, Kennedy M, Forman M, Sjögren M, Margolin R, Chen X, Farlow MR, Dean RA, Waring JF. An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter. Alzheimers Res Ther 2015;7:53. [PMID: 26225140 DOI: 10.1186/s13195-015-0136-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
66 Bakshi P, Jin C, Broutin P, Berhane B, Reed J, Mullan M. Structural optimization of a CXCR2-directed antagonist that indirectly inhibits γ-secretase and reduces Aβ. Bioorganic & Medicinal Chemistry 2009;17:8102-12. [DOI: 10.1016/j.bmc.2009.09.051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
67 Noelker C, Hampel H, Dodel R. Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. Mol Diagn Ther 2011;15:83-102. [PMID: 21623645 DOI: 10.1007/BF03256398] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
68 Cummings JL. Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiol Aging 2010;31:1481-92. [PMID: 20447734 DOI: 10.1016/j.neurobiolaging.2010.03.016] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
69 Panza F, Solfrizzi V, Frisardi V, Imbimbo BP, Capurso C, D’introno A, Colacicco AM, Seripa D, Vendemiale G, Capurso A, Pilotto A. Beyond the neurotransmitter-focused approach in treating Alzheimer’s Disease: drugs targeting β-amyloid and tau protein. Aging Clin Exp Res 2009;21:386-406. [DOI: 10.1007/bf03327445] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 3.9] [Reference Citation Analysis]
70 Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling--are we there yet? Nat Rev Drug Discov. 2014;13:357-378. [PMID: 24781550 DOI: 10.1038/nrd4252] [Cited by in Crossref: 304] [Cited by in F6Publishing: 273] [Article Influence: 43.4] [Reference Citation Analysis]
71 D'Avanzo C, Sliwinski C, Wagner SL, Tanzi RE, Kim DY, Kovacs DM. γ-Secretase modulators reduce endogenous amyloid β42 levels in human neural progenitor cells without altering neuronal differentiation. FASEB J 2015;29:3335-41. [PMID: 25903103 DOI: 10.1096/fj.15-271015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
72 Galasko D. Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. Front Neurol 2015;6:256. [PMID: 26733934 DOI: 10.3389/fneur.2015.00256] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
73 Ullah R, Khan M, Shah SA, Saeed K, Kim MO. Natural Antioxidant Anthocyanins-A Hidden Therapeutic Candidate in Metabolic Disorders with Major Focus in Neurodegeneration. Nutrients 2019;11:E1195. [PMID: 31141884 DOI: 10.3390/nu11061195] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 20.0] [Reference Citation Analysis]
74 Willis BA, Zhang W, Ayan-Oshodi M, Lowe SL, Annes WF, Sirois PJ, Friedrich S, de la Peña A. Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants. J Clin Pharmacol 2012;52:904-13. [PMID: 21724950 DOI: 10.1177/0091270011407195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
75 Sano M. Tarenflurbil: mechanisms and myths. Arch Neurol 2010;67:750-2. [PMID: 20558395 DOI: 10.1001/archneurol.2010.94] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
76 Penninkilampi R, Brothers HM, Eslick GD. Pharmacological Agents Targeting γ-Secretase Increase Risk of Cancer and Cognitive Decline in Alzheimer's Disease Patients: A Systematic Review and Meta-Analysis. J Alzheimers Dis 2016;53:1395-404. [PMID: 27392862 DOI: 10.3233/JAD-160275] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
77 Leclerc B, Abulrob A. Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. ScientificWorldJournal 2013;2013:589308. [PMID: 23476143 DOI: 10.1155/2013/589308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
78 Hyde LA, Zhang Q, Del Vecchio RA, Leach PT, Cohen-Williams ME, Chen L, Wong GT, McHugh NA, Chen J, Higgins GA, Asberom T, Li W, Pissarnitski D, Levitan D, Nomeir AA, Clader JW, Zhang L, Parker EM. In Vivo Characterization of a Novel γ-Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects. Int J Alzheimers Dis 2013;2013:823528. [PMID: 23573456 DOI: 10.1155/2013/823528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
79 Greenberg BD, Carrillo MC, Ryan JM, Gold M, Gallagher K, Grundman M, Berman RM, Ashwood T, Siemers ER. Improving Alzheimer's disease phase II clinical trials. Alzheimers Dement 2013;9:39-49. [PMID: 23164548 DOI: 10.1016/j.jalz.2012.02.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
80 Delrieu J, Vellas B. [The Alzheimer's disease: how to estimate the impact of the pathology and the treatment?]. Therapie 2010;65:423-8. [PMID: 21144477 DOI: 10.2515/therapie/2010057] [Reference Citation Analysis]
81 Kuruva CS, Reddy PH. Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal. Drug Discov Today 2017;22:223-33. [PMID: 27794478 DOI: 10.1016/j.drudis.2016.10.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
82 Wang Y, Sørensen MG, Zheng Q, Zhang C, Karsdal MA, Henriksen K. Will posttranslational modifications of brain proteins provide novel serological markers for dementias? Int J Alzheimers Dis 2012;2012:209409. [PMID: 22779024 DOI: 10.1155/2012/209409] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
83 Dockens R, Wang J, Castaneda L, Sverdlov O, Huang S, Slemmon R, Gu H, Wong O, Li H, Berman RM, Smith C, Albright CF, Tong G. A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects. Clin Pharmacokinet 2012;51:681-93. [DOI: 10.1007/s40262-012-0005-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
84 Scearce-Levie K, Sanchez PE, Lewcock JW. Leveraging preclinical models for the development of Alzheimer disease therapeutics. Nat Rev Drug Discov 2020;19:447-62. [PMID: 32612262 DOI: 10.1038/s41573-020-0065-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 17.0] [Reference Citation Analysis]
85 Khan TK, Alkon DL. Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy. J Alzheimers Dis 2015;46:817-36. [PMID: 26402622 DOI: 10.3233/JAD-150238] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
86 Massoud F, Gauthier S. Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol 2010;8:69-80. [PMID: 20808547 DOI: 10.2174/157015910790909520] [Cited by in Crossref: 92] [Cited by in F6Publishing: 74] [Article Influence: 9.2] [Reference Citation Analysis]
87 Ow SY, Dunstan DE. A brief overview of amyloids and Alzheimer's disease. Protein Sci 2014;23:1315-31. [PMID: 25042050 DOI: 10.1002/pro.2524] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 9.3] [Reference Citation Analysis]
88 Rapoport SI, Nelson PT. Biomarkers and evolution in Alzheimer disease. Prog Neurobiol 2011;95:510-3. [PMID: 21801803 DOI: 10.1016/j.pneurobio.2011.07.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
89 Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010;9:387-98. [DOI: 10.1038/nrd2896] [Cited by in Crossref: 718] [Cited by in F6Publishing: 685] [Article Influence: 65.3] [Reference Citation Analysis]
90 Schellekens H, McNamara O, Dinan TG, McCarthy JV, McGlacken GP, Cryan JF. Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor. J Pharm Pharmacol 2013;65:528-38. [PMID: 23488781 DOI: 10.1111/jphp.12010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
91 Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, Andreasson U, Siemers E, Mawuenyega KG, Sigurdson WC, May PC, Paul SM, Holtzman DM, Blennow K, Bateman RJ. Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease. J Alzheimers Dis 2012;31:335-41. [PMID: 22531418 DOI: 10.3233/JAD-2012-120508] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
92 Brothers HM, Gosztyla ML, Robinson SR. The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease. Front Aging Neurosci 2018;10:118. [PMID: 29922148 DOI: 10.3389/fnagi.2018.00118] [Cited by in Crossref: 116] [Cited by in F6Publishing: 108] [Article Influence: 38.7] [Reference Citation Analysis]
93 Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 2014;76:185-205. [PMID: 24853080 DOI: 10.1002/ana.24188] [Cited by in Crossref: 177] [Cited by in F6Publishing: 155] [Article Influence: 25.3] [Reference Citation Analysis]
94 Rauk A. The chemistry of Alzheimer’s disease. Chem Soc Rev 2009;38:2698. [DOI: 10.1039/b807980n] [Cited by in Crossref: 310] [Cited by in F6Publishing: 292] [Article Influence: 25.8] [Reference Citation Analysis]
95 Dees C, Zerr P, Tomcik M, Beyer C, Horn A, Akhmetshina A, Palumbo K, Reich N, Zwerina J, Sticherling M. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum. 2011;63:1396-1404. [PMID: 21312186 DOI: 10.1002/art.30254] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
96 Sultzer DL, Melrose RJ, Harwood DG, Campa O, Mandelkern MA. Effect of memantine treatment on regional cortical metabolism in Alzheimer's disease. Am J Geriatr Psychiatry 2010;18:606-14. [PMID: 20220580 DOI: 10.1097/JGP.0b013e3181ca3a4e] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
97 Ozudogru SN, Lippa CF. Disease modifying drugs targeting β-amyloid. Am J Alzheimers Dis Other Demen 2012;27:296-300. [PMID: 22815077 DOI: 10.1177/1533317512452034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
98 Duara R, Loewenstein DA, Potter E, Appel J, Greig MT, Urs R, Shen Q, Raj A, Small B, Barker W. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology. 2008;71:1986-1992. [PMID: 19064880 DOI: 10.1212/01.wnl.0000336925.79704.9f] [Cited by in Crossref: 145] [Cited by in F6Publishing: 124] [Article Influence: 12.1] [Reference Citation Analysis]
99 Gilbert CA, Daou MC, Moser RP, Ross AH. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res 2010;70:6870-9. [PMID: 20736377 DOI: 10.1158/0008-5472.CAN-10-1378] [Cited by in Crossref: 82] [Cited by in F6Publishing: 52] [Article Influence: 7.5] [Reference Citation Analysis]
100 Chen SY, Gao Y, Sun JY, Meng XL, Yang D, Fan LH, Xiang L, Wang P. Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer's Disease. Front Pharmacol 2020;11:497. [PMID: 32390843 DOI: 10.3389/fphar.2020.00497] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
101 Panza F, Solfrizzi V, Frisardi V, Capurso C, D’Introno A, Colacicco AM, Vendemiale G, Capurso A, Imbimbo BP. Disease-modifying approach to the treatment of Alzheimer’s disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging. 2009;26:537-555. [PMID: 19655822 DOI: 10.2165/11315770-000000000-00000] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 5.7] [Reference Citation Analysis]
102 Sabbagh MN. Drug development for Alzheimer's disease: where are we now and where are we headed? Am J Geriatr Pharmacother 2009;7:167-85. [PMID: 19616185 DOI: 10.1016/j.amjopharm.2009.06.003] [Cited by in Crossref: 95] [Cited by in F6Publishing: 89] [Article Influence: 7.9] [Reference Citation Analysis]
103 Chen Y, Zheng S, Qi D, Zheng S, Guo J, Zhang S, Weng Z. Inhibition of Notch signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS One. 2012;7:e46512. [PMID: 23056328 DOI: 10.1371/journal.pone.0046512] [Cited by in Crossref: 78] [Cited by in F6Publishing: 92] [Article Influence: 8.7] [Reference Citation Analysis]
104 Wei B, Chen L, Li R, Tian J. Stem cells in gastrointestinal cancers: a matter of choice in cell fate determination. Expert Rev Anticancer Ther. 2010;10:1621-1633. [PMID: 20942633 DOI: 10.1586/era.10.52] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
105 Schröder B, Saftig P. Intramembrane proteolysis within lysosomes. Ageing Res Rev 2016;32:51-64. [PMID: 27143694 DOI: 10.1016/j.arr.2016.04.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
106 Nikseresht S, Bush AI, Ayton S. Treating Alzheimer's disease by targeting iron. Br J Pharmacol 2019;176:3622-35. [PMID: 30632143 DOI: 10.1111/bph.14567] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
107 Takai T, Hoashi Y, Tomata Y, Morimoto S, Nakamura M, Watanabe T, Igari T, Koike T. Discovery of novel 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine derivatives as γ-secretase modulators. Bioorganic & Medicinal Chemistry Letters 2015;25:4245-9. [DOI: 10.1016/j.bmcl.2015.07.101] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
108 Wolfe MS. γ-Secretase as a target for Alzheimer's disease. Adv Pharmacol 2012;64:127-53. [PMID: 22840746 DOI: 10.1016/B978-0-12-394816-8.00004-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
109 Pettersson M, Kauffman GW, am Ende CW, Patel NC, Stiff C, Tran TP, Johnson DS. Novel γ-secretase modulators: a review of patents from 2008 to 2010. Expert Opin Ther Pat 2011;21:205-26. [PMID: 21231889 DOI: 10.1517/13543776.2011.547479] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
110 Krishna BM, Jana S, Singhal J, Horne D, Awasthi S, Salgia R, Singhal SS. Notch signaling in breast cancer: From pathway analysis to therapy. Cancer Lett 2019;461:123-31. [PMID: 31326555 DOI: 10.1016/j.canlet.2019.07.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
111 Lehman NL. The ubiquitin proteasome system in neuropathology. Acta Neuropathol 2009;118:329-47. [PMID: 19597829 DOI: 10.1007/s00401-009-0560-x] [Cited by in Crossref: 141] [Cited by in F6Publishing: 134] [Article Influence: 11.8] [Reference Citation Analysis]
112 Schenk D, Basi GS, Pangalos MN. Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med 2012;2:a006387. [PMID: 22951439 DOI: 10.1101/cshperspect.a006387] [Cited by in Crossref: 62] [Cited by in F6Publishing: 70] [Article Influence: 6.9] [Reference Citation Analysis]
113 Creed MC, Milgram NW. Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications. Age (Dordr) 2010;32:365-84. [PMID: 20640545 DOI: 10.1007/s11357-010-9142-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
114 D'onofrio G, Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Paroni G, Cascavilla L, Seripa D, Pilotto A. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease. Expert Opinion on Drug Discovery 2011;7:19-37. [DOI: 10.1517/17460441.2012.645534] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
115 Raven F, Ward JF, Zoltowska KM, Wan Y, Bylykbashi E, Miller SJ, Shen X, Choi SH, Rynearson KD, Berezovska O, Wagner SL, Tanzi RE, Zhang C. Soluble Gamma-secretase Modulators Attenuate Alzheimer's β-amyloid Pathology and Induce Conformational Changes in Presenilin 1. EBioMedicine 2017;24:93-101. [PMID: 28919280 DOI: 10.1016/j.ebiom.2017.08.028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
116 Richter LR, Wan Q, Wen D, Zhang Y, Yu J, Kang JK, Zhu C, McKinnon EL, Gu Z, Qiang L, Pajvani UB. Targeted Delivery of Notch Inhibitor Attenuates Obesity-Induced Glucose Intolerance and Liver Fibrosis. ACS Nano 2020;14:6878-86. [PMID: 32441510 DOI: 10.1021/acsnano.0c01007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
117 Herman F, Westfall S, Brathwaite J, Pasinetti GM. Suppression of Presymptomatic Oxidative Stress and Inflammation in Neurodegeneration by Grape-Derived Polyphenols. Front Pharmacol 2018;9:867. [PMID: 30210334 DOI: 10.3389/fphar.2018.00867] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
118 Wagner SL, Rynearson KD, Duddy SK, Zhang C, Nguyen PD, Becker A, Vo U, Masliah D, Monte L, Klee JB, Echmalian CM, Xia W, Quinti L, Johnson G, Lin JH, Kim DY, Mobley WC, Rissman RA, Tanzi RE. Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606. J Pharmacol Exp Ther 2017;362:31-44. [PMID: 28416568 DOI: 10.1124/jpet.117.240861] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
119 Kim D, Kim YS, Shin DW, Park CS, Kang JH. Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges. J Clin Neurol 2016;12:381-92. [PMID: 27819412 DOI: 10.3988/jcn.2016.12.4.381] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
120 Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 2010;223:334-46. [PMID: 19815015 DOI: 10.1016/j.expneurol.2009.09.024] [Cited by in Crossref: 102] [Cited by in F6Publishing: 100] [Article Influence: 8.5] [Reference Citation Analysis]
121 De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb Perspect Med 2012;2:a006304. [PMID: 22315713 DOI: 10.1101/cshperspect.a006304] [Cited by in Crossref: 260] [Cited by in F6Publishing: 246] [Article Influence: 32.5] [Reference Citation Analysis]
122 Siemers ER. How can we recognize "disease modification" effects? J Nutr Health Aging 2009;13:341-3. [PMID: 19300873 DOI: 10.1007/s12603-009-0036-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
123 Merrill MJ, Edwards NA, Lonser RR. Notch receptor and effector expression in von Hippel-Lindau disease-associated central nervous system hemangioblastomas. J Neurosurg 2011;115:512-7. [PMID: 21663414 DOI: 10.3171/2011.5.JNS11271] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
124 Menke V, van Es JH, de Lau W, van den Born M, Kuipers EJ, Siersema PD, de Bruin RW, Kusters JG, Clevers H. Conversion of metaplastic Barrett's epithelium into post-mitotic goblet cells by gamma-secretase inhibition. Dis Model Mech 2010;3:104-10. [PMID: 20075383 DOI: 10.1242/dmm.003012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
125 Brendel M, Jaworska A, Herms J, Trambauer J, Rötzer C, Gildehaus FJ, Carlsen J, Cumming P, Bylund J, Luebbers T, Bartenstein P, Steiner H, Haass C, Baumann K, Rominger A. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment. Mol Psychiatry 2015;20:1179-87. [PMID: 26055427 DOI: 10.1038/mp.2015.74] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
126 Woodward MC. Drug Treatments in Development for Alzheimer's Disease. Journal of Pharmacy Practice and Research 2012;42:58-65. [DOI: 10.1002/j.2055-2335.2012.tb00133.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
127 Herrmann N, Chau SA, Kircanski I, Lanctôt KL. Current and Emerging Drug Treatment Options for Alzheimerʼs Disease: A Systematic Review. Drugs 2011;71:2031-65. [DOI: 10.2165/11595870-000000000-00000] [Cited by in Crossref: 140] [Cited by in F6Publishing: 131] [Article Influence: 14.0] [Reference Citation Analysis]
128 Bullain S, Doody R. What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials. J Neurochem 2020;155:120-36. [PMID: 32277473 DOI: 10.1111/jnc.15023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
129 Chong CM, Su H, Lu JJ, Wang Y. The effects of bioactive components from the rhizome of Salvia miltiorrhiza (Danshen) on the characteristics of Alzheimer's disease. Chin Med 2019;14:19. [PMID: 31139246 DOI: 10.1186/s13020-019-0242-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
130 Toyn JH, Ahlijanian MK. Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β. Alzheimers Res Ther 2014;6:14. [PMID: 25031632 DOI: 10.1186/alzrt244] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
131 Hampel H, Lista S. Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. J Nutr Health Aging 2013;17:54-63. [PMID: 23299381 DOI: 10.1007/s12603-013-0003-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
132 Walsh C, Drinkenburg W, Ahnaou A. Neurophysiological assessment of neural network plasticity and connectivity: Progress towards early functional biomarkers for disease interception therapies in Alzheimer’s disease. Neuroscience & Biobehavioral Reviews 2017;73:340-58. [DOI: 10.1016/j.neubiorev.2016.12.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
133 Soares HD, Gasior M, Toyn JH, Wang JS, Hong Q, Berisha F, Furlong MT, Raybon J, Lentz KA, Sweeney F, Zheng N, Akinsanya B, Berman RM, Thompson LA, Olson RE, Morrison J, Drexler DM, Macor JE, Albright CF, Ahlijanian MK, AbuTarif M. The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers. J Pharmacol Exp Ther 2016;358:138-50. [PMID: 27189973 DOI: 10.1124/jpet.116.232256] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
134 Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ. Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol 2010;120:385-99. [PMID: 20652578 DOI: 10.1007/s00401-010-0723-9] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
135 Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Med 2009;7:7. [PMID: 19228370 DOI: 10.1186/1741-7015-7-7] [Cited by in Crossref: 110] [Cited by in F6Publishing: 106] [Article Influence: 9.2] [Reference Citation Analysis]
136 Uddin MS, Kabir MT, Rahman MS, Behl T, Jeandet P, Ashraf GM, Najda A, Bin-Jumah MN, El-Seedi HR, Abdel-Daim MM. Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease. Int J Mol Sci 2020;21:E5858. [PMID: 32824102 DOI: 10.3390/ijms21165858] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 24.0] [Reference Citation Analysis]
137 Roy M, Cardoso C, Dorieux O, Malgorn C, Epelbaum S, Petit F, Kraska A, Brouillet E, Delatour B, Perret M, Aujard F, Dhenain M. Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition. Neurobiol Aging 2015;36:149-56. [PMID: 25131002 DOI: 10.1016/j.neurobiolaging.2014.07.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
138 Juryńczyk M, Selmaj K. Notch: a new player in MS mechanisms. J Neuroimmunol 2010;218:3-11. [PMID: 19748685 DOI: 10.1016/j.jneuroim.2009.08.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
139 Kabir MT, Uddin MS, Mamun AA, Jeandet P, Aleya L, Mansouri RA, Ashraf GM, Mathew B, Bin-Jumah MN, Abdel-Daim MM. Combination Drug Therapy for the Management of Alzheimer's Disease. Int J Mol Sci 2020;21:E3272. [PMID: 32380758 DOI: 10.3390/ijms21093272] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 30.0] [Reference Citation Analysis]
140 Hill DLG, Schwarz AJ, Isaac M, Pani L, Vamvakas S, Hemmings R, Carrillo MC, Yu P, Sun J, Beckett L, Boccardi M, Brewer J, Brumfield M, Cantillon M, Cole PE, Fox N, Frisoni GB, Jack C, Kelleher T, Luo F, Novak G, Maguire P, Meibach R, Patterson P, Bain L, Sampaio C, Raunig D, Soares H, Suhy J, Wang H, Wolz R, Stephenson D. Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. Alzheimers Dement 2014;10:421-429.e3. [PMID: 24985687 DOI: 10.1016/j.jalz.2013.07.003] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 8.5] [Reference Citation Analysis]
141 Galeano D, Li S, Gerstein M, Paccanaro A. Predicting the frequencies of drug side effects. Nat Commun 2020;11:4575. [PMID: 32917868 DOI: 10.1038/s41467-020-18305-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
142 Giuffrida ML, Caraci F, De Bona P, Pappalardo G, Nicoletti F, Rizzarelli E, Copani A. The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology. Rev Neurosci 2010;21:83-93. [PMID: 20614800 DOI: 10.1515/revneuro.2010.21.2.83] [Cited by in Crossref: 52] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
143 Desai P, Shete H, Adnaik R, Disouza J, Patravale V. Therapeutic targets and delivery challenges for Alzheimer’s disease. World J Pharmacol 2015; 4(3): 236-264 [DOI: 10.5497/wjp.v4.i3.236] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Bartesaghi R, Guidi S, Ciani E. Is it possible to improve neurodevelopmental abnormalities in Down syndrome? Reviews in the Neurosciences 2011;22. [DOI: 10.1515/rns.2011.037] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
145 Wolfe MS. γ-Secretase inhibitors and modulators for Alzheimer's disease. J Neurochem 2012;120 Suppl 1:89-98. [PMID: 22122056 DOI: 10.1111/j.1471-4159.2011.07501.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 93] [Article Influence: 9.4] [Reference Citation Analysis]
146 Léger GC, Massoud F. Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease. Expert Review of Clinical Pharmacology 2014;6:423-42. [DOI: 10.1586/17512433.2013.811237] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
147 Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B. Biomarkers for Alzheimer's disease therapeutic trials. Progress in Neurobiology 2011;95:579-93. [DOI: 10.1016/j.pneurobio.2010.11.005] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 8.5] [Reference Citation Analysis]
148 Hampel H, Prvulovic D. Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective. J Nutr Health Aging 2012;16:346-8. [PMID: 22499455 DOI: 10.1007/s12603-012-0021-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
149 Galimberti D, Scarpini E. Disease-modifying treatments for Alzheimer's disease. Ther Adv Neurol Disord 2011;4:203-16. [PMID: 21765871 DOI: 10.1177/1756285611404470] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 8.4] [Reference Citation Analysis]
150 Imbimbo BP. Alzheimer's disease: γ-secretase inhibitors. Drug Discovery Today: Therapeutic Strategies 2008;5:169-75. [DOI: 10.1016/j.ddstr.2008.10.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
151 Broadstock M, Ballard C, Corbett A. Latest treatment options for Alzheimer’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Expert Opinion on Pharmacotherapy 2014;15:1797-810. [DOI: 10.1517/14656566.2014.936848] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
152 Ayton S, Lei P, Bush AI. Biometals and their therapeutic implications in Alzheimer's disease. Neurotherapeutics 2015;12:109-20. [PMID: 25354461 DOI: 10.1007/s13311-014-0312-z] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 17.8] [Reference Citation Analysis]
153 Lleó A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N, Ghidoni R, Lewczuk P, Jeromin A, Winblad B, Tsolaki M, Mroczko B, Visser PJ, Santana I, Svenningsson P, Blennow K, Aarsland D, Molinuevo JL, Zetterberg H, Mollenhauer B. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol 2015;11:41-55. [PMID: 25511894 DOI: 10.1038/nrneurol.2014.232] [Cited by in Crossref: 103] [Cited by in F6Publishing: 89] [Article Influence: 14.7] [Reference Citation Analysis]
154 Przybyłowska M, Kowalski S, Dzierzbicka K, Inkielewicz-Stepniak I. Therapeutic Potential of Multifunctional Tacrine Analogues. Curr Neuropharmacol 2019;17:472-90. [PMID: 29651948 DOI: 10.2174/1570159X16666180412091908] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
155 Pannee J, Törnqvist U, Westerlund A, Ingelsson M, Lannfelt L, Brinkmalm G, Persson R, Gobom J, Svensson J, Johansson P, Zetterberg H, Blennow K, Portelius E. The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease. Neuroscience Letters 2014;573:7-12. [DOI: 10.1016/j.neulet.2014.04.041] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
156 Wagner SL, Zhang C, Cheng S, Nguyen P, Zhang X, Rynearson KD, Wang R, Li Y, Sisodia SS, Mobley WC, Tanzi RE. Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species. Biochemistry 2014;53:702-13. [PMID: 24401146 DOI: 10.1021/bi401537v] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
157 Watari H, Shimada Y, Tohda C. New Treatment for Alzheimer's Disease, Kamikihito, Reverses Amyloid-β-Induced Progression of Tau Phosphorylation and Axonal Atrophy. Evid Based Complement Alternat Med 2014;2014:706487. [PMID: 24707311 DOI: 10.1155/2014/706487] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
158 Basi GS, Hemphill S, Brigham EF, Liao A, Aubele DL, Baker J, Barbour R, Bova M, Chen XH, Dappen MS, Eichenbaum T, Goldbach E, Hawkinson J, Lawler-Herbold R, Hu K, Hui T, Jagodzinski JJ, Keim PS, Kholodenko D, Latimer LH, Lee M, Marugg J, Mattson MN, McCauley S, Miller JL, Motter R, Mutter L, Neitzel ML, Ni H, Nguyen L, Quinn K, Ruslim L, Semko CM, Shapiro P, Smith J, Soriano F, Szoke B, Tanaka K, Tang P, Tucker JA, Ye XM, Yu M, Wu J, Xu YZ, Garofalo AW, Sauer JM, Konradi AW, Ness D, Shopp G, Pleiss MA, Freedman SB, Schenk D. Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease. Alzheimers Res Ther 2010;2:36. [PMID: 21190552 DOI: 10.1186/alzrt60] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
159 Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB. Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease. Clinical Neuropharmacology 2010;33:67-73. [DOI: 10.1097/wnf.0b013e3181cb577a] [Cited by in Crossref: 140] [Cited by in F6Publishing: 60] [Article Influence: 12.7] [Reference Citation Analysis]
160 Yamamoto K, Yamamoto R, Kato N. Amyloid β and Amyloid Precursor Protein Synergistically Suppress Large-Conductance Calcium-Activated Potassium Channel in Cortical Neurons. Front Aging Neurosci 2021;13:660319. [PMID: 34149396 DOI: 10.3389/fnagi.2021.660319] [Reference Citation Analysis]
161 Cummings JL. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement 2011;7:e13-44. [PMID: 21550318 DOI: 10.1016/j.jalz.2010.06.004] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 7.4] [Reference Citation Analysis]
162 Awasthi M, Singh S, Pandey VP, Dwivedi UN. Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products. Journal of the Neurological Sciences 2016;361:256-71. [DOI: 10.1016/j.jns.2016.01.008] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 15.6] [Reference Citation Analysis]
163 Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry 2018;19:244-328. [PMID: 29076399 DOI: 10.1080/15622975.2017.1375556] [Cited by in Crossref: 118] [Cited by in F6Publishing: 112] [Article Influence: 29.5] [Reference Citation Analysis]
164 Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JN, Sullenger BA. Notch promotes radioresistance of glioma stem cells. Stem Cells. 2010;28:17-28. [PMID: 19921751 DOI: 10.1002/stem.261] [Cited by in Crossref: 77] [Cited by in F6Publishing: 268] [Article Influence: 7.0] [Reference Citation Analysis]
165 Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131-144. [PMID: 20157306 DOI: 10.1038/nrneurol.2010.4] [Cited by in Crossref: 1108] [Cited by in F6Publishing: 1065] [Article Influence: 100.7] [Reference Citation Analysis]
166 Szeto JY, Lewis SJ. Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia. Curr Neuropharmacol 2016;14:326-38. [PMID: 26644155 DOI: 10.2174/1570159x14666151208112754] [Cited by in Crossref: 77] [Cited by in F6Publishing: 32] [Article Influence: 15.4] [Reference Citation Analysis]
167 Rashid U, Ansari FL. Challenges in Designing Therapeutic Agents for Treating Alzheimer’s Disease-from Serendipity to Rationality. Drug Design and Discovery in Alzheimer's Disease. Elsevier; 2014. pp. 40-141. [DOI: 10.1016/b978-0-12-803959-5.50002-7] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
168 Reiss AB, Montufar N, DeLeon J, Pinkhasov A, Gomolin IH, Glass AD, Arain HA, Stecker MM. Alzheimer Disease Clinical Trials Targeting Amyloid: Lessons Learned From Success in Mice and Failure in Humans. Neurologist 2021;26:52-61. [PMID: 33646990 DOI: 10.1097/NRL.0000000000000320] [Reference Citation Analysis]
169 Puzzo D, Arancio O. Amyloid-β peptide: Dr. Jekyll or Mr. Hyde? J Alzheimers Dis 2013;33 Suppl 1:S111-20. [PMID: 22735675 DOI: 10.3233/JAD-2012-129033] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
170 Bittner T, Fuhrmann M, Burgold S, Jung CK, Volbracht C, Steiner H, Mitteregger G, Kretzschmar HA, Haass C, Herms J. Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J Neurosci 2009;29:10405-9. [PMID: 19692615 DOI: 10.1523/JNEUROSCI.2288-09.2009] [Cited by in Crossref: 78] [Cited by in F6Publishing: 60] [Article Influence: 6.5] [Reference Citation Analysis]
171 Elvang AB, Volbracht C, Pedersen LØ, Jensen KG, Karlsson JJ, Larsen SA, Mørk A, Stensbøl TB, Bastlund JF. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J Neurochem 2009;110:1377-87. [PMID: 19519664 DOI: 10.1111/j.1471-4159.2009.06215.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
172 Schneider P, Hampel H, Buerger K. Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther. 2009;15:358-374. [PMID: 19840034 DOI: 10.1111/j.1755-5949.2009.00104.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 88] [Article Influence: 8.2] [Reference Citation Analysis]
173 Hopkins CR. ACS chemical neuroscience molecule spotlight on semagacestat (LY450139). ACS Chem Neurosci 2010;1:533-4. [PMID: 22778845 DOI: 10.1021/cn1000606] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
174 Blennow K, Zetterberg H, Haass C, Finucane T. Semagacestat's fall: where next for AD therapies? Nat Med 2013;19:1214-5. [PMID: 24100981 DOI: 10.1038/nm.3365] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
175 Pandey G, Ramakrishnan V. Invasive and non-invasive therapies for Alzheimer's disease and other amyloidosis. Biophys Rev 2020;12:1175-86. [PMID: 32930962 DOI: 10.1007/s12551-020-00752-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
176 Zetterberg H, Mattsson N, Blennow K, Olsson B. Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Alzheimers Res Ther 2010;2:32. [PMID: 21122172 DOI: 10.1186/alzrt56] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
177 Demetrius LA, Driver JA. Preventing Alzheimer's disease by means of natural selection. J R Soc Interface 2015;12:20140919. [PMID: 25551134 DOI: 10.1098/rsif.2014.0919] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
178 Karran E. Current status of vaccination therapies in Alzheimer's disease. J Neurochem 2012;123:647-51. [PMID: 23050679 DOI: 10.1111/jnc.12009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
179 Sun Z, Asberom T, Bara T, Bennett C, Burnett D, Chu I, Clader J, Cohen-williams M, Cole D, Czarniecki M, Durkin J, Gallo G, Greenlee W, Josien H, Huang X, Hyde L, Jones N, Kazakevich I, Li H, Liu X, Lee J, Maccoss M, Mandal MB, Mccracken T, Nomeir A, Mazzola R, Palani A, Parker EM, Pissarnitski DA, Qin J, Song L, Terracina G, Vicarel M, Voigt J, Xu R, Zhang L, Zhang Q, Zhao Z, Zhu X, Zhu Z. Cyclic Hydroxyamidines as Amide Isosteres: Discovery of Oxadiazolines and Oxadiazines as Potent and Highly Efficacious γ-Secretase Modulators in Vivo. J Med Chem 2012;55:489-502. [DOI: 10.1021/jm201407j] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
180 Cummings J, Zhong K. Biomarker-Driven Therapeutic Management of Alzheimer’s Disease: Establishing the Foundations. Clin Pharmacol Ther 2013;95:67-77. [DOI: 10.1038/clpt.2013.205] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
181 Saxena U. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here? Expert Opinion on Therapeutic Targets 2010;14:1273-7. [DOI: 10.1517/14728222.2010.528285] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
182 Hsu CK, Hsu CC, Lee JY, Kuo YM, Pai MC. Exacerbation of psoriatic skin lesions in a patient with Alzheimer disease receiving gamma-secretase inhibitor. J Am Acad Dermatol 2013;68:e46-8. [PMID: 23317986 DOI: 10.1016/j.jaad.2012.07.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
183 Doody RS, Raman R, Sperling RA, Seimers E, Sethuraman G, Mohs R, Farlow M, Iwatsubo T, Vellas B, Sun X, Ernstrom K, Thomas RG, Aisen PS; Alzheimer’s Disease Cooperative Study. Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease. Alzheimers Res Ther 2015;7:36. [PMID: 26064192 DOI: 10.1186/s13195-015-0121-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
184 Khansari PS, Coyne L. NSAIDs in the treatment and/or prevention of neurological disorders. Inflammopharmacol 2012;20:159-67. [DOI: 10.1007/s10787-011-0116-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
185 Bi P, Kuang S. Notch signaling as a novel regulator of metabolism. Trends Endocrinol Metab 2015;26:248-55. [PMID: 25805408 DOI: 10.1016/j.tem.2015.02.006] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 14.8] [Reference Citation Analysis]
186 Revadigar V, Ghalib RM, Murugaiyah V, Embaby MA, Jawad A, Mehdi SH, Hashim R, Sulaiman O. Enzyme Inhibitors Involved in the Treatment of Alzheimer’s Disease. Drug Design and Discovery in Alzheimer's Disease. Elsevier; 2014. pp. 142-98. [DOI: 10.1016/b978-0-12-803959-5.50003-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
187 Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors. Pharmacology & Therapeutics 2012;134:8-25. [DOI: 10.1016/j.pharmthera.2011.12.002] [Cited by in Crossref: 136] [Cited by in F6Publishing: 121] [Article Influence: 15.1] [Reference Citation Analysis]
188 Yu Y, Logovinsky V, Schuck E, Kaplow J, Chang MK, Miyagawa T, Wong N, Ferry J. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects. J Clin Pharmacol 2014;54:528-36. [PMID: 24343761 DOI: 10.1002/jcph.249] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
189 De-paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer’s Disease. In: Harris JR, editor. Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease. Dordrecht: Springer Netherlands; 2012. pp. 329-52. [DOI: 10.1007/978-94-007-5416-4_14] [Cited by in Crossref: 151] [Cited by in F6Publishing: 132] [Article Influence: 16.8] [Reference Citation Analysis]
190 Han J, Shen Q. Targeting γ-secretase in breast cancer. Breast Cancer (Dove Med Press). 2012;4:83-90. [PMID: 24367196 DOI: 10.2147/bctt.s26437] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
191 Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E, Blennow K. A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther 2010;2:7. [PMID: 20350302 DOI: 10.1186/alzrt30] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 6.3] [Reference Citation Analysis]
192 Tong G, Castaneda L, Wang J, Sverdlov O, Huang S, Slemmon R, Gu H, Wong O, Li H, Berman RM, Smith C, Albright C, Dockens RC. Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men. Clin Drug Investig 2012;32:761-9. [DOI: 10.1007/s40261-012-0006-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
193 Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006221. [PMID: 22951438 DOI: 10.1101/cshperspect.a006221] [Cited by in Crossref: 100] [Cited by in F6Publishing: 104] [Article Influence: 11.1] [Reference Citation Analysis]
194 Nigam V, Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol 2009;47:828-34. [PMID: 19695258 DOI: 10.1016/j.yjmcc.2009.08.008] [Cited by in Crossref: 138] [Cited by in F6Publishing: 120] [Article Influence: 11.5] [Reference Citation Analysis]
195 Alley GM, Bailey JA, Chen D, Ray B, Puli LK, Tanila H, Banerjee PK, Lahiri DK. Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J Neurosci Res 2010;88:143-54. [PMID: 19642202 DOI: 10.1002/jnr.22172] [Cited by in Crossref: 80] [Cited by in F6Publishing: 82] [Article Influence: 7.3] [Reference Citation Analysis]
196 Mandal M, Zhu Z, Cumming JN, Liu X, Strickland C, Mazzola RD, Caldwell JP, Leach P, Grzelak M, Hyde L, Zhang Q, Terracina G, Zhang L, Chen X, Kuvelkar R, Kennedy ME, Favreau L, Cox K, Orth P, Buevich A, Voigt J, Wang H, Kazakevich I, Mckittrick BA, Greenlee W, Parker EM, Stamford AW. Design and Validation of Bicyclic Iminopyrimidinones As Beta Amyloid Cleaving Enzyme-1 (BACE1) Inhibitors: Conformational Constraint to Favor a Bioactive Conformation. J Med Chem 2012;55:9331-45. [DOI: 10.1021/jm301039c] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
197 Takai T, Koike T, Honda E, Kajita Y, Nakamura M, Morimoto S, Hoashi Y, Kamata M, Watanabe T, Igari T, Terauchi J. Design and synthesis of piperazine derivatives as a novel class of γ-secretase modulators that selectively lower Aβ42 production. Bioorganic & Medicinal Chemistry 2015;23:1923-34. [DOI: 10.1016/j.bmc.2015.03.055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
198 Tagami S, Yanagida K, Kodama TS, Takami M, Mizuta N, Oyama H, Nishitomi K, Chiu Y, Okamoto T, Ikeuchi T, Sakaguchi G, Kudo T, Matsuura Y, Fukumori A, Takeda M, Ihara Y, Okochi M. Semagacestat Is a Pseudo-Inhibitor of γ-Secretase. Cell Reports 2017;21:259-73. [DOI: 10.1016/j.celrep.2017.09.032] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
199 Satlin A, Wang J, Logovinsky V, Berry S, Swanson C, Dhadda S, Berry DA. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease. Alzheimers Dement (N Y) 2016;2:1-12. [PMID: 29067290 DOI: 10.1016/j.trci.2016.01.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
200 Siemers E, DeMattos RB, May PC, Dean RA. Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials. Biomark Med 2010;4:81-9. [PMID: 20387304 DOI: 10.2217/bmm.09.85] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
201 Matsunoshita Y, Ijiri K, Ishidou Y, Nagano S, Yamamoto T, Nagao H, Komiya S, Setoguchi T. Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1. PLoS One 2011;6:e16234. [PMID: 21283769 DOI: 10.1371/journal.pone.0016234] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
202 Duara R, Loewenstein DA, Greig-Custo MT, Raj A, Barker W, Potter E, Schofield E, Small B, Schinka J, Wu Y, Potter H. Diagnosis and staging of mild cognitive impairment, using a modification of the clinical dementia rating scale: the mCDR. Int J Geriatr Psychiatry 2010;25:282-9. [PMID: 19565573 DOI: 10.1002/gps.2334] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
203 Castro MA, Hadziselimovic A, Sanders CR. The vexing complexity of the amyloidogenic pathway. Protein Sci 2019;28:1177-93. [PMID: 30897251 DOI: 10.1002/pro.3606] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
204 Bennett DA, Yu L, De Jager PL. Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease. Biochem Pharmacol 2014;88:617-30. [PMID: 24508835 DOI: 10.1016/j.bcp.2014.01.037] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
205 Andrade C, Radhakrishnan R. The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments. Indian J Psychiatry 2009;51:12-25. [PMID: 19742190 DOI: 10.4103/0019-5545.44900] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
206 Falk R, Falk A, Dyson MR, Melidoni AN, Parthiban K, Young JL, Roake W, McCafferty J. Generation of anti-Notch antibodies and their application in blocking Notch signalling in neural stem cells. Methods 2012;58:69-78. [PMID: 22842086 DOI: 10.1016/j.ymeth.2012.07.008] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
207 Ritter A, Cummings J. Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. Front Neurol 2015;6:186. [PMID: 26379620 DOI: 10.3389/fneur.2015.00186] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
208 Chen YX, Weng ZH, Zhang SL. Notch3 regulates the activation of hepatic stellate cells. World J Gastroenterol 2012; 18(12): 1397-1403 [PMID: 22493555 DOI: 10.3748/wjg.v18.i12.1397] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
209 Maraver A, Fernández-Marcos PJ, Herranz D, Muñoz-Martin M, Gomez-Lopez G, Cañamero M, Mulero F, Megías D, Sanchez-Carbayo M, Shen J, Sanchez-Cespedes M, Palomero T, Ferrando A, Serrano M. Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 2012;22:222-34. [PMID: 22897852 DOI: 10.1016/j.ccr.2012.06.014] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 9.9] [Reference Citation Analysis]
210 Jia Q, Deng Y, Qing H. Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials. Biomed Res Int 2014;2014:837157. [PMID: 25136630 DOI: 10.1155/2014/837157] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
211 Thambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med 2010;4:65-79. [PMID: 20387303 DOI: 10.2217/bmm.09.84] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 9.9] [Reference Citation Analysis]
212 Tomita T. Secretase inhibitors and modulators for Alzheimer’s disease treatment. Expert Review of Neurotherapeutics 2014;9:661-79. [DOI: 10.1586/ern.09.24] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 14.0] [Reference Citation Analysis]